serum bilirubin level was 21 mg/dl. Infant was treated with phototherapy and phenobarbitone for 4 days. Infant's serum bilirubin level was still high (total -20.4 mg/dl, direct -6.3 mg/dl) and infant was noticed to have dark discoloration of the entire body. Phototherapy was continued for 2 more days, and two-dimensional echocardiogram (2D Echo) was performed with suspicion of cyanotic heart disease (dark pigmentation being interpreted as cyanosis) which revealed tiny ventricular septal defect (VSD) with cystic mass in liver compressing inferior vena cava (IVC). Parents were counseled for the need of emergency surgery to remove the mass.
INTRODUCTION
B ronze baby syndrome is the dark grey-brown pigmentation of skin, mucous membrane, and urine following phototherapy. Hepatic dysfunction has to be there for this condition to be present. We report a neonate with dark brown pigmentation of the skin. Lesions were spread over the abdomen, chest, back, and both upper and lower limb after receiving phototherapy for neonatal jaundice.
CASE REPORT
This term 2.6 kg birth weight, appropriate for gestational age, female neonate was born to a 26-year-old primigravida mother by forceps-assisted vaginal delivery. Infant is a product of consanguineous marriage. Antenatal period was uneventful. Baby did not cry immediately after birth and required resuscitation (details not known). Infant required oxygen supplementation for a day in view of transient tachypnea of newborn (TTNB). Infant was noticed to have yellowish discoloration of life on day 2 of life. Infant's The infant was noticed to have dark brown pigmentation of the entire body [ Figure 1 ]. There was cephalhematoma in the right parietal region. Infant's systemic examination was unremarkable except for a systolic murmur. Infant's 2D Echo revealed tiny mid-muscular VSD and IVC displaced to midline due to cystic mass below diaphragm. Computed tomography scan of the abdomen was performed which revealed presence of a right adrenal hematoma. Liver and gall bladder were normal.
Infant was diagnosed to have Bronze baby syndrome and was evaluated for a possible cause. Infant was passing dark colored urine and clay colored stools. Infant's serum bilirubin level was 14.8 mg//dl with direct bilirubin being 7.2 mg/dl. Infant's rest of the liver function tests were normal. Infant's metabolic parameters were normal, and blood sugar levels were within euglycemic range. Infant's urine was negative for reducing substances. Infant's HIDA scan was performed after priming with phenobarbitone for 5 days which was suggestive of extrahepatic biliary atresia [ Figure 2 ].
DISCUSSION
It is assumed that abnormal accumulation of photoisomer of bilirubin is the cause of this condition. The second cause postulated is abnormal hepatic function leading to copper-porphyrin complex which is photo destroyed leading to brown pigmentation. The third explanation is an accumulation of biliverdin leading to pigmentation. It is probably due to a reduction in hepatic excretory function of bilirubin photoproducts. The pigment accumulated in the body may be polymerized and forms bilifuscin-like substances following a free radical reaction. It is concluded that the brown pigment is formed via unknown pigment. [1] It should be differentiated from gray baby syndrome exclusively seen in neonates and very young infants receiving high doses of chloramphenicol. The infant is cyanosed, acidotic, has cold peripheries and has the signs of all of the marked hypotonia, poor feeding, vomiting, loose stools, and a distended abdomen.
No treatment is required for the bronze baby syndrome as the pigmentation slowly disappears after stopping phototherapy. Three cases have been reported; there was one case each of bile duct atresia, galactosemia, and parenteral nutrition with cholestasis. The bronze color disappears spontaneously, and the prognosis is dependent on the causative liver disease for which investigations should be performed routinely. [2] It is essential to identify the underlying liver disease to determine the prognosis of this syndrome.
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